ProCE Banner Activity

Rational Combination Strategies in the Treatment of EGFR-Mutated NSCLC With Acquired Resistance to EGFR TKI Therapy: Updates From ASCO 2022

Clinical Thought
In this commentary, a lung cancer expert highlights advances from ASCO 2022 in the management of EGFR-mutated NSCLC with acquired resistance to first-line EGFR TKI therapy using rational combination regimens composed of third-generation EGFR TKIs, EGFR monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates.

Released: July 13, 2022

Expiration: July 12, 2023

No longer available for credit.

Share

Faculty

Jonathan Riess

Jonathan Riess, MD, MS

Associate Professor
Division of Hematology-Oncology
Department of Internal Medicine
UC Davis
Medical Director
Thoracic Oncology
UC Davis Comprehensive Cancer Center
Sacramento, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Jonathan Riess, MD, MS

Associate Professor
Division of Hematology-Oncology
Department of Internal Medicine
UC Davis
Medical Director
Thoracic Oncology
UC Davis Comprehensive Cancer Center
Sacramento, California

Jonathan Riess, MD, MS: consultant/advisor/speaker: BeiGene, Blueprint, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Jazz, Novartis, Regeneron; researcher: AstraZeneca, GlaxoSmithKline, Merck, Novartis, Revolution Medicines, Spectrum.